X

Trial Profile

A Phase 1b/2 Trial of Dupilumab Given in Conjunction With PD-1 or PD-L1 Blockade in the Treatment of Relapsed/Refractory Metastatic NSCLC

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary) ; Programmed cell death 1 receptor modulators; Programmed cell death-1 ligand-1 modulators
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Sep 2023 Planned End Date changed from 1 Sep 2025 to 1 Dec 2024.
25 Sep 2023 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2024.
19 Apr 2023 Trial design, presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com